Why the study?
How transcription factors differentially regulate RNA polymerase II recruitment versus transcriptional elongation during cardiac hypertrophy remains unknown, and the scope of gene regulation by FoxO1 remains unexplored.
Population
Mouse hearts and in vitro cardiomyocytes
Comparison
Isoproterenol injections or transverse aortic constriction vs vehicle injection/sham surgery, and FoxO1 knockdown/deletion
Design
Preclinical animal and in vitro mechanistic study
Follow-up
7 days
Authors
Loading...
FoxO1 may coordinate pol II dynamics in hypertrophy; hypothesis-generating for transcription factor-targeted therapies in HF.
FoxO1 mediates cardiac hypertrophic growth through extensive regulation of RNA polymerase II dynamics, highlighting its potential as a therapeutic target in cardiac hypertrophy.
Pfleger et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: